Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000998615 | SCV001154761 | uncertain significance | not provided | 2017-10-01 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001332353 | SCV001524650 | uncertain significance | Combined oxidative phosphorylation defect type 8 | 2019-01-10 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV000998615 | SCV002165719 | uncertain significance | not provided | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 227 of the AARS2 protein (p.Asp227Asn). This variant is present in population databases (rs765016818, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with AARS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 809943). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AARS2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |